RESEARCH NOTE

REVISED Effect of LXR/RXR agonism on brain and CSF A β 40 levels in rats [version 2; peer review: 1 approved, 2 approved with reservations]

Songli Wang¹, Paul Wen², Stephen Wood²

¹Genome Analysis Unit, Amgen Inc., San Francisco, CA, USA

²Department of Neuroscience, Amgen Inc., Thousand Oaks, CA, USA

v2 First published: 04 Feb 2016, 5:138
<https://doi.org/10.12688/f1000research.7868.1>

Latest published: 19 Apr 2016, 5:138
<https://doi.org/10.12688/f1000research.7868.2>

Abstract

Alzheimer's disease (AD) is characterized pathologically by the presence of amyloid plaques and neurofibrillary tangles. The amyloid hypothesis contends that the abnormal accumulation of A β , the principal component of amyloid plaques, plays an essential role in initiating the disease. Impaired clearance of soluble A β from the brain, a process facilitated by apolipoprotein E (APOE), is believed to be a contributing factor in plaque formation. APOE expression is transcriptionally regulated through the action of a family of nuclear receptors including the peroxisome proliferator-activated receptor gamma and liver X receptors (LXRs) in coordination with retinoid X receptors (RXRs). It has been previously reported that various agonists of this receptor family can influence brain A β levels in rodents. In this study we investigated the effects of LXR/RXR agonism on brain and cerebrospinal fluid (CSF) levels of A β 40 in naïve rats. Treatment of rats for 3 days or 7 days with the LXR agonist, T0901317 or the RXR agonist, bexarotene did not result in significant changes in brain or CSF A β 40 levels.

Keywords

Alzheimer's , Apolipoprotein E , A β , liver X receptor , retinoid X receptor , Bexarotene

This article is included in the **Preclinical Reproducibility and Robustness** gateway.

Open Peer Review

Approval Status ✓ ? ?

	1	2	3
version 2 (revision) 19 Apr 2016			? view
version 1 04 Feb 2016	✓ view	? view	
<ol style="list-style-type: none"> Sam Gandy , Mount Sinai School of Medicine, New York, USA Mary Jo LaDu, University of Illinois at Chicago, Chicago, USA Ana Valencia, University of Illinois at Chicago, Chicago, USA Conor Smith, University of Illinois at Chicago, Chicago, USA Daniel M. Michaelson, Tel Aviv University, Tel Aviv, Israel 			

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Stephen Wood (stephenw@amgen.com)

Competing interests: All authors are employees and stockholders of Amgen, Inc.

Grant information: All work was funded by Amgen Inc.

Copyright: © 2016 Wang S *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Wang S, Wen P and Wood S. **Effect of LXR/RXR agonism on brain and CSF A β 40 levels in rats [version 2; peer review: 1 approved, 2 approved with reservations]** F1000Research 2016, 5:138 <https://doi.org/10.12688/f1000research.7868.2>

First published: 04 Feb 2016, 5:138 <https://doi.org/10.12688/f1000research.7868.1>

REVISED Amendments from Version 1

Summary of revisions

Introduction

Provided further background and context to the current study with additional references to prior work with LXR agonists (Burns 2006, Riddell 2007) including work in a model similar to the one used in our study, non-transgenic rats (Suon 2010). Also included reviews of the work with the RXR agonist, bexarotene (Tesseur and De Strooper 2013 and Tousi 2015).

Conclusion

Expanded the conclusion section to reconcile the findings from the current study with other work in this field. Specifically acknowledged several hypotheses associated with LXR/RXR agonism that were not addressed in this study.

Highlights include:

1. Differences in findings between labs could very well be a result of a variety of factors related to the methodologies employed
2. We recognize that LXR/RXR agonism may affect the pathology of AD in other ways (e.g. increased phagocytic clearance of amyloid deposits (Savage 2015) or may directly affect the cognitive decline via non-Aβ-dependent mechanisms not yet fully understood (Jack 2016)
3. Aβ42 was not measured nor was regional Aβ analysis performed in the brain
4. APP transgenic mice were not used in this study therefore amyloid plaque burden or cognitive changes previously described using these mice could not be assessed
5. Because the current study used non-transgenic rats, the impact of human APOE or APOE isoform-specific effects on LXR/RXR agonism, something others have shown to be an important variable, were beyond the scope of this study (Youmans 2012) (Tai 2014) (Boehm-Cagan 2014)
6. Mentioned newly published data from a human clinical trial with bexarotene (Cummings 2016)

Figures and Tables

Corrected the mis-labeling of the vehicle in [Figure 1a](#) ("Vehicle 3" changed to "Vehicle 4")

See referee reports**Introduction**

Alzheimer's disease (AD) is a debilitating neurodegenerative disease and the leading cause of dementia in the elderly. It is currently estimated that 5 million people in the US and 30 million worldwide are afflicted with this disease. The pathological hallmarks of AD are the presence of extracellular amyloid plaques and intracellular neurofibrillary tangles in the hippocampus and cortical areas of the brain¹. The core constituent of the amyloid plaques is a 4 kDa peptide known as amyloid-β peptide (Aβ). Aggregation of Aβ into soluble, multimeric assemblies and insoluble amyloid fibrils is hypothesized to contribute directly to the pathogenesis of AD; therefore therapeutic strategies aimed at lowering soluble Aβ levels in the brain would be predicted to have a disease-modifying effect².

The E4 allele of apolipoprotein E (APOE) is the largest genetic risk factor for sporadic, late-onset AD. The presence of a single copy of E4 increases the risk for Alzheimer's disease 3-fold and individuals with 2 copies are 15 times more likely to develop AD³. Data showing that APOE4 carriers begin to accumulate amyloid deposits earlier in life relative to non-carriers⁴ has led to the hypothesis that increased risk associated with an E4 genotype may be the result of the effects of APOE on Aβ production, turnover and/or clearance from the central nervous system (CNS).

The expression of genes encoding lipid-transport proteins, including APOE is transcriptionally regulated by the ligand-activated nuclear receptors, peroxisome proliferator-activated receptor gamma (PPARγ) and liver X receptors (LXRs) which form obligate heterodimers with retinoid X receptors (RXRs)⁵. Additionally, activation of these receptors has been shown to affect the activation state of macrophage and microglia⁶. Based on the processes influenced by this nuclear receptor family it is a reasonable hypothesis that agonism of one or more members of the family could have beneficial effects on Aβ homeostasis in the CNS. In fact, several groups have demonstrated that LXR agonism with either GW3965⁷ or T0901317^{8–11} results in reduced amyloid plaque burden and/or soluble Aβ levels in amyloid precursor protein (APP) transgenic mouse models. Using non-transgenic rats, Suon *et al.* demonstrated a statistically significant increase in CSF Aβ and a decrease in soluble brain Aβ following T0901317 treatment¹². In addition, it was reported that a highly selective, blood-brain-barrier-permeant, RXR agonist, bexarotene (Targretin), enhanced clearance of soluble Aβ in an APP transgenic mouse model in an APOE-dependent manner. In the same study, Aβ plaque burden was reduced by more than 50% within 72 hours. Further, bexarotene treatment also resulted in a similar reduction (~25%) in brain interstitial fluid (ISF) levels of Aβ in non-transgenic, C57Bl/6 mice 7–12 hours following a single administration¹³. Attempts to replicate the bexarotene findings resulted in mixed results (see reviews by Tesseur & De Strooper¹⁴ and Tousi¹⁵). This study aims to examine the robustness of the hypothesis that RXR or LXR agonism affects soluble Aβ homeostasis in the CNS.

Materials and methods

In vivo pharmacodynamic studies: All procedures were approved by the Amgen Institutional Animal Care and Use Committee. Young male Sprague-Dawley rats (175–200 g) were purchased from Harlan (Indianapolis, IN) and were maintained on a 12h light/dark cycle with unrestricted access to food and water until use. Rats were dosed orally for 3 and 7 consecutive days with AMG8155, a proprietary small molecule BACE1 inhibitor, at 3 mg/kg in 2% HPMC and 1% Tween 80, pH 2, bexarotene (Alfa Aesar, Ward Hill, MA) at 100 mg/kg in 30% Labrasol, 1% Tween 20, 2% Providone and 0.05% BHA, pH7.0 (Vehicle 3), and T0901317, a LXR agonist (Fisher Scientific, Pittsburgh, PA), at 30 mg/kg in 0.5% NaCl, 2% Tween 80 (Vehicle 4). 4 hours post dose on the last day of study, rats were euthanized with CO₂ inhalation for 2 minutes and the cisterna magna was quickly exposed by removing the skin and muscle above it. Cerebrospinal fluid (CSF) was collected with a 30 gauge needle inserted through the dura membrane

covering the cisterna magna. CSF samples with visible blood contamination were discarded. Blood was withdrawn by cardiac puncture and plasma was obtained by centrifugation at 15,000 rpm for 10 min at 4°C for drug exposure. Brains were removed and, along with the CSF, immediately frozen on dry ice and stored at -80°C until use. The frozen brains were subsequently homogenized in 10 volumes (w/v) of 0.5% Triton X-100 in TBS with protease inhibitors cocktails. The homogenates were centrifuged at 355,000 rpm for 30 min at 4°C.

Quantification of Aβ40 and APOE in brain and CSF: Samples are analyzed for Aβ levels by immunoassay with a MSD imager. Briefly, 96-well avidin plates (MesoScale Discovery, Inc., Gaithersburg, MD) were coated with biotinylated-anti-Aβ antibody 4G8 (mouse monoclonal, Cat# Sig 39240-1000, Covance Research Products, Princeton, NJ) at 10 µg/ml in PBS. Samples were co-incubated in the plate overnight at 4°C along with a ruthenium-labeled anti-Aβ antibody specific for the C-terminal region of Aβ40 (ConFab40; Amgen, Thousand Oaks, CA). Plates were then washed, 150 µl/well read buffer T (MesoScale Discovery, Inc.) was added, and plates were read immediately on a Sector 6000 imager according to the manufacturer's recommended protocol (MesoScale Discovery, Inc.). All samples were assayed in triplicate and analyzed by using Prism version 5.04 (GraphPad Software Inc., San Diego, CA). Data was analyzed by one-way analysis of variance and Dunnett's multiple comparison test.

APOE levels in brain (50 µg homogenates) and CSF (10 µl) were analyzed by Western blot following PAGE using 4–12% Bis-Tris gels (Invitrogen, Carlsbad, CA). Blots were probed with primary antibodies to APOE (goat polyclonal, EMD Millipore; 1:1000) and the loading control, actin (ThermoFisher Scientific; 1:200) for 60 min at 4°C and then washed with TBST (Tris-buffered saline, 0.1% Tween 20) three times at room temperature, followed by (Goat-anti-mouse) secondary antibody (ThermoFisher Scientific; 1:1000) for 30 min at 4°C. Densitometric analysis of ApoE was performed (exposure time of 4 minutes with a relative intensity of 2.0, Odyssey imaging system, with application software Version 3.0) followed by an unpaired t-test using GraphPad Prism 5.04 software.

Measurement of Plasma, CSF, and Brain Drug Concentration: Aliquots of plasma (50 µl) were combined with 300 µl of acetonitrile containing 125 µl structurally related internal standard (IS), vortexed, and centrifuged. Supernatant was transferred into a plain polypropylene 96-well plate for sample analysis. Brain tissue samples were homogenized by using a Covaris (Woburn, MA) acoustic homogenizer. Aliquots of 50 µl homogenate were combined with acetonitrile containing a structurally related IS, vortexed, and centrifuged at 1,900 g for 5 minutes. Supernatant was transferred into a 96-well plate for sample analysis. Analytical standards and tissues were measured by liquid chromatography mass spectrometry (Shimadzu Pumps Autosampler Prominence for HPLC and

PE Sciex API 4000 for MS, with Analyst 1.6.1 software) using atmospheric-pressure chemical ionization and multiple reaction monitoring in the positive ion mode.

Results

Our aim in this study was to investigate the effects of RXR/LXR agonism on Aβ homeostasis in the CNS of non-transgenic rats using the RXR agonist, bexarotene and the LXR agonist, T0901317. As a positive control, we included a β-secretase inhibitor (AMG8155). Compounds and appropriate vehicle controls were administered to naïve Sprague Dawley rats at doses indicated in [Table 1](#) for either 3 or 7 consecutive days.

Following 3 and 7 days of dosing, animals were evaluated for both compound levels and pharmacodynamic endpoints. APOE levels were quantitated in brain homogenate and CSF by Western blot. Aβ40 levels were quantitated in the same compartments using immunoassay as described in the Materials and methods section. Following 3 and 7 days of dosing, APOE levels were increased in brain and CSF in the T0901317 treated animals compared to vehicle treated animals ([Figure 1](#)). Changes in CSF were statistically significant at both 3 (p = 0.0002) and 7 days (p = 0.0007) whereas changes in brain were statistically significant at day 3 (p = 0.030) but did not reach significance at day 7 (p = 0.056). Bexarotene treatment also resulted in a statistically significant increase in CSF APOE levels compared to vehicle treated animals following both 3 (p = 0.019) and 7 days (p = 0.002) of dosing ([Figure 2](#)). APOE levels in brain following bexarotene treatment trended towards an increase however these changes were not statistically significant. Soluble Aβ40 levels were unchanged in brain and CSF following 3-day ([Figure 3](#)) and 7-day ([Figure 4](#)) treatment with either bexarotene or T0901317. The positive control BACE inhibitor, AMG8155 effectively reduced Aβ40 levels by 70% and 71% in CSF and by 67% and 69% in brain in the 3-day and 7-day studies respectively ([Figure 3](#) and [Figure 4](#)).

Drug levels of bexarotene and T0901317 were measured in plasma and brain homogenate following 3 and 7 days of dosing ([Table 2](#)). Total levels of both compounds achieved single-digit to low double-digit µM levels in brain and showed good uptake in brain relative to plasma in both dosing paradigms.

Table 1. Dosing Table.

Group	Dose (mg/kg)
Bexarotene	100
AMG8155	3
T0901317	30

[Table 1](#) lists the 3 compounds tested in this study along with the respective doses (mg/kg).

Figure 1. LXR agonist, TO901317 significantly increased APOE levels in rat CSF following 3 and 7 days of dosing at 30 mg/kg. APOE was also increased in brain however the changes only reached statistical significance at day 3. **A)** Western blot analysis of APOE in brain and CSF. **B)** Densitometric analysis of the bands was performed as described in the Materials and Methods section; data are presented as the mean plus standard deviation; Vehicle 4 (black bars) and TO901317 (gray bars).

Figure 2. RXR agonist, bexarotene significantly increased APOE in rat CSF following 3 and 7 days of dosing at 100 mg/kg. APOE changes in brain were not statistically significant. **A)** Western blot analysis of APOE in brain and CSF. **B)** Densitometric analysis of the bands was performed as described in the Materials and Methods section; data are presented as the mean plus standard deviation; Vehicle 4 (black bars) and bexarotene (gray bars).

Figure 3. Aβ40 levels in (A) CSF and (B) brain were unchanged following 3 days of treatment with bexarotene (triangles) or T0901317 (diamonds). Positive control BACE inhibitor AMG8155 (squares) reduced Aβ40 levels 70 and 67% in CSF and brain respectively following a single administration.

Figure 4. Aβ40 levels in (A) CSF and (B) brain were unchanged following 7 days of treatment with bexarotene (triangles) or T0901317 (diamonds). Positive control BACE inhibitor AMG8155 (squares) reduced Aβ40 levels 71 and 69% in CSF and brain respectively following a single administration.

Table 2. Compound Exposure Table.

Treatment Duration	Compound	[brain] _t , μ M	[plasma] _t , μ M	[brain] _t /[plasma] _t
3 days	Bexarotene (100 mg/kg)	6.26	5.74	1.09
	T0901317 (30 mg/kg)	14.44	5.30	2.72
7 days	Bexarotene (100 mg/kg)	3.41	4.76	0.72
	T0901317 (30 mg/kg)	11.68	4.30	2.72

Following 3 and 7 days of dosing, compound levels were measure in brain homogenate and plasma. Total (t) compound concentrations (μ M) are reported in each case. The brain to plasma ratio is also shown (far right-hand column).

Conclusion

In this study we demonstrate that 3-day or 7-day treatment of naïve rats with the LXR agonist, T0901317 or the RXR agonist, bexarotene treatment results in an increase in APOE levels in CSF without observable effects on CSF or brain A β 40 levels.

Although this study sought to examine the robustness of the hypothesis that RXR/LXR agonism affects soluble A β homeostasis, it was not designed to explicitly replicate any one prior study. Differences in findings between labs could very well be a result of a variety of factors related to the methodologies employed, something that has been nicely reviewed for bexarotene previously^{14,15}.

Whereas the current report was focused solely on soluble A β , we recognize that RXR/LXR agonism may affect AD pathology in other ways (e.g. increased phagocytic clearance of amyloid deposits¹⁶). LXR or RXR agonism may also affect cognitive decline in AD patients via non-A β -dependent mechanisms not yet fully understood¹⁷. Moreover, this study exclusively assessed A β 40 and it remains possible that LXR/RXR agonism may result in A β 42-specific changes. In most prior studies that have examined changes in soluble A β 40 and A β 42 homeostasis, both A β species are affected in a similar manner. However, one published report showed that LXR agonism with T0901317 resulted in a selective reduction in A β 42 in the hippocampus only¹¹. Such region-specific changes would not have been detected under our current experimental protocol as whole brain homogenates were analyzed.

Finally, others have shown that the effects of LXR/RXR agonism vary depending on APOE isoform. Treatment of EFAD mice (mice expressing 5XFAD mutations and h-APOE3 or h-APOE4)¹⁸ with bexarotene or bexarotene analog, LG100268, resulted in an increase in APOE4 lipidation and subsequent decrease in soluble, oligomeric A β levels¹⁹. Likewise, in naïve human APOE3 or APOE4 targeted replacement mice, bexarotene treatment increased APOE4 lipidation and decreased E4-associated A β 42

and hyperphosphorylated tau accumulation in the hippocampus²⁰. The current study was performed in naïve rats expressing endogenous APOE, therefore, human APOE isoform-specific effects would have been beyond the scope of this study.

It remains to be seen how well any of these preclinical findings translate to human clinical trials. Recently, the effect of bexarotene on amyloid burden was assessed in patients with Alzheimer's disease (AD) in a small, proof-of-concept trial²¹. Although the primary outcome of the trial was negative, data suggest that bexarotene resulted in lowering of amyloid burden in APOE4 non-carriers.

We hope that these findings will stimulate future discussion in the Alzheimer's research community on the impact of LXR/RXR agonism on central A β homeostasis.

Data availability

Open Science Framework: Dataset: Effect of LXR/RXR agonism on brain and CSF A β 40 levels in rats, doi: [10.17605/OSF.IO/3NS64](https://doi.org/10.17605/OSF.IO/3NS64)²²

Author contributions

S. Wang: *Participated in research design; wrote or contributed to the writing of the manuscript.*

P. Wen: *Participated in research design; conducted experiments; performed data analysis; wrote or contributed to the writing of the manuscript.*

S. Wood: *Participated in research design; performed data analysis; wrote or contributed to the writing of the manuscript.*

Competing interests

All authors are employees and stockholders of Amgen, Inc.

Grant information

All work was funded by Amgen Inc.

References

1. Citron M: **Alzheimer's disease: strategies for disease modification.** *Nat Rev Drug Discov.* 2010; **9**(5): 387–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Hardy J, Selkoe DJ: **The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.** *Science.* 2002; **297**(5580): 353–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Yu JT, Tan L, Hardy J: **Apolipoprotein E in Alzheimer's disease: an update.** *Annu Rev Neurosci.* 2014; **37**: 79–100.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Morris JC, Roe CM, Xiong C, *et al.*: **APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.** *Ann Neurol.* 2010; **67**(1): 122–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Chawla A, Boisvert WA, Lee CH, *et al.*: **A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis.** *Mol Cell.* 2001; **7**(1): 161–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Hong C, Tontonoz P: **Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors.** *Curr Opin Genet Dev.* 2008; **18**(5): 461–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Jiang Q, Lee CY, Mandrekar S, *et al.*: **ApoE promotes the proteolytic degradation of Abeta.** *Neuron.* 2008; **58**(5): 681–93.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Koldamova RP, Lefterov IM, Staufienbiel M, *et al.*: **The liver X receptor ligand T0901317 decreases amyloid beta production *in vitro* and in a mouse model of Alzheimer's disease.** *J Biol Chem.* 2005; **280**(6): 4079–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Fitz NF, Cronican A, Pham T, *et al.*: **Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice.** *J Neurosci.* 2010; **30**(20): 6862–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Burns MP, Vardanian L, Pajoohesh-Ganji A, *et al.*: **The effects of ABCA1 on cholesterol efflux and Abeta levels *in vitro* and *in vivo*.** *J Neurochem.* 2006; **98**(3): 792–800.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Riddell DR, Zhou H, Comery TA, *et al.*: **The LXR agonist T0901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease.** *Mol Cell Neurosci.* 2007; **34**(4): 621–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Suon S, Zhao J, Villarreal SA, *et al.*: **Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid- β peptides in the cerebral spinal fluid of rats.** *Mol Neurodegener.* 2010; **5**: 44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Cramer PE, Cirrito JR, Wesson DW, *et al.*: **ApoE-directed therapeutics rapidly clear β -amyloid and reverse deficits in AD mouse models.** *Science.* 2012; **335**(6075): 1503–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Tesseur I, De Strooper B: **When the dust settles: what did we learn from the bexarotene discussion?** *Alzheimers Res Ther.* 2013; **5**(6): 54.
[PubMed Abstract](#) | [Free Full Text](#)
15. Tousse B: **The emerging role of bexarotene in the treatment of Alzheimer's disease: current evidence.** *Neuropsychiatr Dis Treat.* 2015; **11**: 311–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Savage JC, Jay T, Goduni E, *et al.*: **Nuclear receptors license phagocytosis by trem2⁺ myeloid cells in mouse models of Alzheimer's disease.** *J Neurosci.* 2015; **35**(16): 6532–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Jack CR Jr, Knopman DS, Chételetat G, *et al.*: **Suspected non-Alzheimer disease pathophysiology - concept and controversy.** *Nat Rev Neurol.* 2016; **12**(2): 117–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Youmans KL, Tai LM, Nwabuisi-Heath E, *et al.*: **APOE4-specific changes in A β accumulation in a new transgenic mouse model of Alzheimer disease.** *J Biol Chem.* 2012; **287**(50): 41774–86.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Tai LM, Koster KP, Luo J, *et al.*: **Amyloid- β pathology and APOE genotype modulate retinoid X receptor agonist activity *in vivo*.** *J Biol Chem.* 2014; **289**(44): 30538–55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Boehm-Cagan A, Michaelson DM: **Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene.** *J Neurosci.* 2014; **34**(21): 7293–301.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Cummings JL, Zhong K, Kinney JW, *et al.*: **Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer's disease.** *Alzheimers Res Ther.* 2016; **8**(1): 4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Wang S, Wen PH, Wood S: **Dataset: Effect of LXR/RXR Agonism on Brain and CSF A β 40 Levels in Rats.** *Open Science Framework.* 2016.
[Data Source](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 11 May 2016

<https://doi.org/10.5256/f1000research.9090.r12557>

© 2016 Michaelson D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Daniel M. Michaelson

Department of Neurobiology, Sagol School of Neurosciences, Myriam Lebach Chair in Molecular Neurodegeneration, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel

This communication revealed that treatment of rats with the LXR/RXR agonists bexarotene and T0901317 increased the brain levels of apoE but had no effect on the levels of Ab40.

A key issue which is not yet resolved in this paper, and which I believe is important, is whether the present treatments with the LXR/RXR agonists in the rat result in partial/weak activation of the LXR/RXR system which affects the levels of apoE but not of the other related readout parameter (i.e. Ab40 in this case) or that the LXR/RXR system is robustly activated by the presently employed paradigm but that this does not affect the levels of Ab40.

Assessment of the "on target" effects of such pharmacological manipulations is important for determination of the significance and meaning of the Ab40 related negative finding and for addressing and reconciling difference between this study and previous reports (eg ref 12 of Suon et al 2010). Accordingly, we suggest that the expression of additional LXR/RXR driven genes be monitored (eg ABCA1 by either western blots or PCR) and if possible also Ab42.

The Suon study was performed utilizing a forebrain + hippocampus brain extract of 1 month old rat. The possible role of differences in these parameters in mediating the differences between the effects of the RXR/RXR treatment in the Suon study and the present manuscript should be discussed.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Version 1

Reviewer Report 02 March 2016

<https://doi.org/10.5256/f1000research.8469.r12696>

© 2016 LaDu M et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mary Jo LaDu

Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, USA

Conor Smith

Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, USA

Ana Valencia

Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, USA

In this manuscript, Wang and colleagues report that treatment for 3 and 7 d bexarotene (Bex, an RXR agonist) or T0901317 (TO, an LXR agonist) induce an increase in apoE levels and but have no effect on A β 40 in the CSF and brain of rats. While the subject matter is timely, the conclusions must be taken with reservations because of three major concerns:

1. Limited readouts and regions analyzed. It has been previously demonstrated that changes in the levels of A β 40 and apoE in CSF and brain do not always correlate with efficacy in FAD-Tg mice^{1,2}. Furthermore, it has been shown that an increase of apoE levels by Bex can be beneficial or detrimental depending on the isoform of apoE³ or the brain region analyzed³.
2. The exclusion of A β 42. It has been reported that CSF A β 42 levels, and not A β 40, are increased in AD patients compared to controls⁴.
3. Comparison to previous reports. Suon and colleagues (2010)⁵ treated rats with LXR agonists TO (at the same dose) or GW3965 and reported an increase in apoE that correlated with an increase in A β 40/42 levels in CSF and a reduction of A β 40 in brain⁵. Wang and colleagues should reconcile their results with this work specifically and interpret their work in the context of the field in general.

A minor observation is that in Figure 1A the vehicle is mislabeled as Vehicle 3 (should be Vehicle 4 for T0901317)

Within the AD field, there is an ongoing discussion of the effects of Bex on soluble and deposited A β levels in the brain and cognition, with contradictory findings. This is likely due to several confounding factors, including: variance within and across models and inconsistencies in the methods used to characterize and quantify the proteins of interest, particularly soluble A β . It is imperative to take these parameters into account when considering the efficacy of RXR or LXR agonists for AD therapeutics. As well, a phase I trial of Bex in AD patients recently concluded⁶. While these results may be of limited significance and were not available for the submission of this manuscript, inclusion of their results in a revision of the Discussion would be helpful.

References

1. Tesseur I, Lo AC, Roberfroid A, Dietvorst S, et al.: Comment on. *Science*. 2013; **340** (6135): 924-e [PubMed Abstract](#) | [Publisher Full Text](#)
2. Boehm-Cagan A, Michaelson DM: Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene. *J Neurosci*. 2014; **34** (21): 7293-301 [PubMed Abstract](#) | [Publisher Full Text](#)
3. Tai LM, Koster KP, Luo J, Lee SH, et al.: Amyloid- β pathology and APOE genotype modulate retinoid X receptor agonist activity in vivo. *J Biol Chem*. 2014; **289** (44): 30538-55 [PubMed Abstract](#) | [Publisher Full Text](#)
4. Blennow K, Mattsson N, Schöll M, Hansson O, et al.: Amyloid biomarkers in Alzheimer's disease. *Trends Pharmacol Sci*. 2015; **36** (5): 297-309 [PubMed Abstract](#) | [Publisher Full Text](#)
5. Suon S, Zhao J, Villarreal SA, Anumula N, et al.: Systemic treatment with liver X receptor agonists raises apolipoprotein E, cholesterol, and amyloid- β peptides in the cerebral spinal fluid of rats. *Mol Neurodegener*. 2010; **5**: 44 [PubMed Abstract](#) | [Publisher Full Text](#)
6. Cummings JL, Zhong K, Kinney JW, Heaney C, et al.: Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer's disease. *Alzheimers Res Ther*. 2016; **8** (1): 4 [PubMed Abstract](#) | [Publisher Full Text](#)

Competing Interests: No competing interests were disclosed.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Reviewer Report 29 February 2016

<https://doi.org/10.5256/f1000research.8469.r12274>

© 2016 Gandy S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sam Gandy

Department of Neurology and Psychiatry, Mount Sinai School of Medicine, New York, NY, USA

Some controversy has surrounded the report in *Science* from Landreth and colleagues showing that bexarotene reduces the brain amyloid plaque burden from APP transgenic mice by 50% or more in a matter of days. Several groups of experts attempted to replicate the dramatic Landreth results but the dramatic results were not replicatable. The current *F1000Research* paper extends that replication attempt story by treating rats with bexarotene and then measuring APP metabolites and apoE in CSF. In agreement with the "second wave" of bexarotene studies, there was no effect of bexarotene on CSF levels of A β 40 or A β 42. The one point of agreement of all studies was that bexarotene does indeed modulate CSF levels of apoE. This argues against the development of bexarotene mimetics as A β lowering agents for the treatment or prevention of Alzheimer's disease. However, inasmuch as elevating apoE may be beneficial in clinical situations via a non-A β -dependent pathway (see <http://www.alzforum.org/news/research-news/bexarotene->

revisited-improves-mouse-memory-no-effect-plaques), bexarotene does reproducibly modulate CSF levels of apoE. The discovery of the entity of SNAP (for review, see Jack *et al.*, 2016¹) indicates that about one-third of clinically diagnosed Alzheimer's patients undergo cognitive decline via some as yet unknown non-A β -dependent pathway.

References

1. Jack CR, Knopman DS, Chtelat G, Dickson D, et al.: Suspected non-Alzheimer disease pathophysiology - concept and controversy. *Nat Rev Neurol*. 2016; **12** (2): 117-24 [PubMed Abstract](#) | [Publisher Full Text](#)

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Comments on this article

Version 1

Reader Comment 11 Feb 2016

Gary Landreth, Case Western Reserve University, USA

Wang *et al.* have reported that they have failed to replicate the ability of bexarotene to clear soluble amyloid from the brain. The reason they failed is straightforward. This experiment has been repeated 6 times. This specific issue has been nicely summarized in a paper published by [Tesseur and De Strooper \(2013\)](#), who were authors of one of the 'Comments' on our Science paper. I draw your attention to the summary table in that paper. The reason Amgen was unable to reproduce our results was that they used the wrong drug formulation. We used the clinically approved formulation of bexarotene (TargretinTM), which is a microcrystalline form of the drug. Those laboratories who used this formulation found drug-induced ApoE expression and lowered Abeta levels. Those studies that solubilized the drug prior to administration failed to replicate the published results. The micronization of bexarotene results in very different pharmacokinetic compared to solubilized drug, which was clearly documented by [Chen *et al.* \(2014; Fig 8a\)](#) and in the FDA filings. The micronized form of the drug is slowly absorbed in the gut and results in sustained plasma (and brain) levels of the drug, whereas the solubilized drug is rapidly absorbed and cleared. The reason this is important is based on the well known mechanisms of nuclear receptor action. Nuclear receptors, like RXR, are ligand-activated transcription factors. Ligand binding to the receptor results in assembly of chromatin remodeling machinery on the enhancers and promoters of its target genes, resulting in epigenetic modifications that open chromatin structure, allowing induction of gene expression. This process takes time, thus there must be sufficiently high drug levels over an extended interval in order for this to be achieved.

The formulation issue was explicitly discussed in the literature and the FDA filing for bexarotene and was detailed on our 'Response' to the 'Comments' in Science ([Landreth *et al.*, 2013](#)). The Amgen scientists (and others) clearly did not make an effort to understand and replicate the original study

design, nor appreciate the importance of the formulation of the drug as it relates to nuclear receptor action. Although the Amgen study was narrowly focused on ApoE and soluble Abeta 40 and did not examine other aspects of our work, the same considerations apply to other contested outcomes of our study.

The Amgen study employed wild type Sprague-Dawley rats, whereas all other studies with bexarotene used murine models of AD. A study of the LXR agonist TO9001317 in rats that was similar to that of Amgen was published by Merck (Suon *et al.*, 2010) and was only partially replicated in the Amgen study and was not cited.

Our work on bexarotene has led to clinical examination of its effects in Alzheimer's disease. Cummings and colleagues published the outcome of a phase II study of bexarotene in mild to moderate AD patients last week (Cummings *et al.*, 2016). While bexarotene treatment did not have a demonstrable effect in individuals possessing an ApoE4 allele, individuals that did not have an ApoE4 gene (representing about 80% of the population) exhibited a robust reduction in brain amyloid with a parallel appearance of Abeta42 in plasma. Thus, a brief 30 day treatment altered two canonical biomarkers of AD in patients with diagnosed disease. These findings are consonant with a recent case report reporting cognitive improvement with bexarotene treatment (Pierrot *et al.* 2015). I hasten to add that the small study size precludes making any hard conclusions from this trial and they should be interpreted cautiously. However, these preliminary clinical findings support and validate our original report using mouse models of the disease.

I don't think the Amgen study adds anything to what was previously known. The work has a logical flaw that undermines the conclusion that they were unable to repeat our study outcomes, including the use of a different model. I think this study is emblematic of the problems associated with reporting 'failure to replicate' findings in studies that do not genuinely reproduce the published work.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research